<DOC>
	<DOCNO>NCT01250795</DOCNO>
	<brief_summary>The purpose study assess safety , immunogenicity , tolerability H5N1 Vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immunogenicity Of A Recombinant H5N1 Vaccine In Adults</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects accept study must meet follow inclusion criterion : Male female age 18 49 year inclusive Able give write informed consent participate Healthy determine medical history , physical examination , vital sign , clinical safety laboratory examination baseline Females fulfill one follow criterion : 1 . At least 1 year postmenopausal 2 . Surgically sterile 3 . Will use oral , implantable , transdermal , injectable contraceptive 30 day prior first vaccination 28 day vaccination 4 . Willing abstain sexual intercourse use another reliable form contraception approve investigator ( e.g. , intrauterine device [ IUD ] , female condom , diaphragm spermicide , cervical cap , use condom sexual partner , sterile sexual partner ) study duration 28 day vaccination Women childbearing potential must negative urine pregnancy test within 24 hour precede receipt dose Comprehension study requirement , express availability require study period , ability attend schedule visit contact telephone throughout followup period Any follow cause exclusion study : Prior receipt influenza vaccine contain H5 Presence significant uncontrolled medical psychiatric illness ( acute chronic ) ; include institution new medical surgical treatment significant dose alteration uncontrolled symptom drug toxicity within 3 month screen reconfirm Day 1 prior vaccination Positive serology human immunodeficiency virus ( HIV 1 HIV 2 ) , hepatitis B surface antigen ( HBsAg ) . hepatitis C ( HCV ) Cancer treatment cancer within 3 year exclude basal cell carcinoma squamous cell carcinoma allow Presence medical condition may associate impaired immune responsiveness , include diabetes mellitus Presently receive ( history receive ) precede 3 month period medication treatment may adversely affect immune system , allergy injection , immune globulin , interferon , immunomodulators , cytotoxic drug ; drug know frequently associate significant major organ toxicity ; systemic ( oral injectable ) corticosteroid ( inhaled topical corticosteroid allow ) Receipt plan administration nonstudy vaccine within 30 day prior vaccination study ( Immunization emergency basis Tetanus Toxoids Adsorbed adult use vaccine—tetanus diphtheria [ Td ] tetanus , diphtheria , pertussis [ Tdap ] 8 day least 8 day dose study vaccine allow , administration study vaccine injection delay nonstudy vaccine administer give soon acceptable [ describe ] provide vaccine administer within 2 week prior study enrollment . ) History significant allergic reaction ( anaphylactictype reaction , respiratory difficulty , angioedema ) inject vaccine study vaccine component History drug chemical abuse year study ; positive urine drug screen screen . Receipt investigational product nonregistered drug within 30 day prior vaccination currently enrol investigational drug study intend enroll study within ensue study period Receipt blood blood product 8 week prior vaccination plan administration study period Donation blood blood product within 8 week prior vaccination time study Acute disease within 72 hour prior vaccination define presence moderate severe illness ( determined investigator medical history physical examination ) without fever , fever &gt; 38ºC orally ( Study vaccine administer person minor illness , diarrhea , mild upper respiratory tract infection without lowgrade fever , vaccination delay subject recover . ) Any condition , opinion investigator , might interfere primary study objective subject 's safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Prevention</keyword>
</DOC>